SIGMA-ALDRICH MATERIAL SAFETY DATA SHEET Date Printed: 11/03/2010 Date Updated: 01/30/2006 Version 1.

4 Section 1 - Product and Company Information Product Name Product Number Brand Company Address Technical Phone: Fax: Emergency Phone: 5,5-DIPHENYLHYDANTOIN 43070 FLUKA Sigma-Aldrich 3050 Spruce Street SAINT LOUIS MO 63103 US 800-325-5832 800-325-5052 314-776-6555

Section 2 - Composition/Information on Ingredient Substance Name 5,5-DIPHENYLHYDANTOIN Formula Synonyms CAS # 57-41-0 SARA 313 Yes

RTECS Number:

C15H12N2O2 Aleviatin * Danten * Dantoinal * Dantoinal klinos * Dantoine * Denyl * Difenilhidantoina (Spanish) * Di-Hydan * Dilabid * Di-Lan * Dintoina * Diphantoin * Diphedan * Diphenylhydantoin * 5,5-Diphenylhydantoin (IUPAC) * Diphenylhydantoine (French) * 5,5-Diphenylimidazolidin-2,4-dione * 5,5-Diphenyl-2,4-imidazolidinedione * DPH * 5,5-Dwufenylohydantoina (Polish) * Ekko capsules * Elepsindon * Enkelfel * Epamin * Epdantoine simple * Fenitoina * Fentoin * Gerot-epilan-D * Hidantal * Hidantilo * Ictalis simple * Kessodanten * Lepsin * Minetoin * NCI-C55765 * Neos-hidantoina * Neosidantoina * Novantoina * OM hidantoina simple * OM-Hydantoine * Phentoin * Phenytoin * Ritmenal * Silantin * Sodanton * Zentropil MU1050000

Section 3 - Hazards Identification EMERGENCY OVERVIEW Toxic. May cause cancer. May cause harm to the unborn child. Harmful if swallowed. Target organ(s): Central nervous system. Blood. Calif. Prop. 65 carcinogen & developmental hazard. HMIS RATING HEALTH: 1* FLAMMABILITY: 0 REACTIVITY: 0 NFPA RATING

HEALTH: 1 FLAMMABILITY: 0 REACTIVITY: 0 *additional chronic hazards present. For additional information on toxicity, please refer to Section 11. Section 4 - First Aid Measures ORAL EXPOSURE If swallowed, wash out mouth with water provided person is conscious. Call a physician. INHALATION EXPOSURE If inhaled, remove to fresh air. If breathing becomes difficult, call a physician. DERMAL EXPOSURE In case of contact, immediately wash skin with soap and copious amounts of water. EYE EXPOSURE In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician. Section 5 - Fire Fighting Measures FLASH POINT N/A AUTOIGNITION TEMP 585 C FLAMMABILITY N/A EXTINGUISHING MEDIA Suitable: Water spray. Carbon dioxide, dry chemical powder, or appropriate foam. FIREFIGHTING Protective Equipment: Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. Specific Hazard(s): Emits toxic fumes under fire conditions. Section 6 - Accidental Release Measures PROCEDURE TO BE FOLLOWED IN CASE OF LEAK OR SPILL Evacuate area. PROCEDURE(S) OF PERSONAL PRECAUTION(S) Wear self-contained breathing apparatus, rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard them after use. METHODS FOR CLEANING UP Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete.

FLUKA - 43070

www.sigma-aldrich.com

Page

Section 7 - Handling and Storage HANDLING User Exposure: Do not breathe dust. Do not get in eyes, on skin, on clothing. Avoid prolonged or repeated exposure. STORAGE Suitable: Keep tightly closed. Section 8 - Exposure Controls / PPE ENGINEERING CONTROLS Use only in a chemical fume hood. Safety shower and eye bath. PERSONAL PROTECTIVE EQUIPMENT Respiratory: Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Hand: Compatible chemical-resistant gloves. Eye: Chemical safety goggles. GENERAL HYGIENE MEASURES Wash contaminated clothing before reuse. Wash thoroughly after handling. Section 9 - Physical/Chemical Properties Appearance Property Molecular Weight pH BP/BP Range MP/MP Range Freezing Point Vapor Pressure Vapor Density Saturated Vapor Conc. Bulk Density Odor Threshold Volatile% VOC Content Water Content Solvent Content Evaporation Rate Viscosity Surface Tension Partition Coefficient Decomposition Temp. Flash Point Explosion Limits Flammability Autoignition Temp Refractive Index Optical Rotation Miscellaneous Data FLUKA - 43070 Color: White Form: Fine crystals Value 252.27 AMU N/A N/A 293 C N/A N/A N/A N/A 0.350 - 0.5 kg/l N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 585 C N/A N/A N/A www.sigma-aldrich.com Page 3 At Temperature or Pressure

Solubility N/A = not available

Solvent: Clear 10 mg/ml acetone

Section 10 - Stability and Reactivity STABILITY Stable: Stable. Conditions of Instability: Readily hydrolyzed. Light. Materials to Avoid: Water. HAZARDOUS DECOMPOSITION PRODUCTS Hazardous Decomposition Products: Carbon monoxide, Carbon dioxide, Nitrogen oxides. HAZARDOUS POLYMERIZATION Hazardous Polymerization: Will not occur Section 11 - Toxicological Information ROUTE OF EXPOSURE Skin Contact: May cause skin irritation. Skin Absorption: May be harmful if absorbed through the skin. Eye Contact: May cause eye irritation. Inhalation: May be harmful if inhaled. Material may be irritating to mucous membranes and upper respiratory tract. Ingestion: Harmful if swallowed. TARGET ORGAN(S) OR SYSTEM(S) Central nervous system. Blood. Gums. SIGNS AND SYMPTOMS OF EXPOSURE Other symptoms include ataxia, slurred speech, blurred vision, nystagmus, mental confusion, hallucinations, and insomnia. Nausea, dizziness, and headache. Gastrointestinal disturbances. TOXICITY DATA Oral Child 100 mg/kg LDLO Oral Rat 1635 mg/kg LD50 Remarks: Behavioral:Muscle weakness. Behavioral:Sleep. Behavioral:Altered sleep time (including change in righting reflex). Intraperitoneal Rat 352 MG/KG LD50 Subcutaneous Rat >1500 MG/KG LD50 Intravenous FLUKA - 43070 www.sigma-aldrich.com Page 4

Rat 101 MG/KG LD50 Remarks: Behavioral:Altered sleep time (including change in righting reflex). Oral Mouse 150 mg/kg LD50 Remarks: Behavioral:Anticonvulsant. Intraperitoneal Mouse 100 MG/KG LD50 Subcutaneous Mouse 110 MG/KG LD50 Intravenous Mouse 92 MG/KG LD50 Intravenous Dog 90 MG/KG LD50 Oral Rabbit > 3000 mg/kg LD50 Intravenous Rabbit 56400 UG/KG LD50 Remarks: Lungs, Thorax, or Respiration:Respiratory stimulation. Behavioral:Convulsions or effect on seizure threshold. Oral Mammal 250 mg/kg LD50 Remarks: Behavioral:Anticonvulsant. CHRONIC EXPOSURE - CARCINOGEN Result: This is or contains a component that has been reported to be carcinogenic based on its IARC, OSHA, ACGIH, NTP, or EPA classification. Species: Woman Route of Application: Oral Result: Tumorigenic:Carcinogenic by RTECS criteria. Tumorigenic Effects: Uterine tumors. Kidney, Ureter, Bladder:Kidney tumors. Species: Woman Route of Application: Oral FLUKA - 43070 www.sigma-aldrich.com Page 5

Result: Brain and Coverings:Tumors. Tumorigenic Effects: Uterine tumors. Tumorigenic:Carcinogenic by RTECS criteria. Species: Woman Route of Application: Oral Dose: 730 MG/KG Exposure Time: 1Y Frequency: C Result: Tumorigenic:Carcinogenic by RTECS criteria. Blood:Lymphomas including Hodgkin's disease. Species: Woman Route of Application: Unreported Result: Tumorigenic:Carcinogenic by RTECS criteria. Brain and Coverings:Tumors. Tumorigenic Effects: Uterine tumors. Species: Woman Route of Application: Unreported Result: Tumorigenic:Carcinogenic by RTECS criteria. Tumorigenic Effects: Uterine tumors. Kidney, Ureter, Bladder:Kidney tumors. Species: Rat Route of Application: Oral Dose: 1500 MG/KG Result: Skin and Appendages: Other: Tumors. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Species: Mouse Route of Application: Oral Dose: 52560 MG/KG Exposure Time: 2Y Frequency: C Result: Tumorigenic:Carcinogenic by RTECS criteria. Liver:Tumors. Species: Rat Route of Application: Oral Dose: 1500 MG/KG Exposure Time: 27D Frequency: I Result: Skin and Appendages: Other: Tumors. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Species: Woman Route of Application: Oral Dose: 730 MG/KG Exposure Time: 1Y Frequency: C Result: Tumorigenic:Carcinogenic by RTECS criteria. Blood:Lymphomas including Hodgkin's disease. Species: Child Route of Application: Oral Dose: 6023 MG/KG Exposure Time: 1Y Frequency: C Result: Skin and Appendages: Other: Tumors. Blood:Lymphomas including Hodgkin's disease. Tumorigenic:Neoplastic by RTECS criteria. Species: Rat Route of Application: Oral Dose: 105 GM/KG FLUKA - 43070 www.sigma-aldrich.com Page 6

Exposure Time: 2Y Frequency: C Result: Liver:Tumors. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Species: Mouse Route of Application: Oral Dose: 5284 MG/KG Exposure Time: 17W Frequency: C Result: Blood:Lymphomas including Hodgkin's disease. Blood:Tumors. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. IARC CARCINOGEN LIST Rating: Group 2B NTP CARCINOGEN LIST Rating: Clear evidence. Species: Mouse Route: Feed CHRONIC EXPOSURE - TERATOGEN Result: May cause congenital malformation in the fetus. Species: Woman Dose: 1080 MG/KG Route of Application: Oral Exposure Time: (1-39W PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Woman Dose: 1620 MG/KG Route of Application: Oral Exposure Time: (1-39W PREG) Result: Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Species: Woman Dose: 1365 MG/KG Route of Application: Oral Exposure Time: (1-39W PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Effects on Newborn: Physical. Effects on Newborn: Delayed effects. Species: Woman Dose: 540 MG/KG Route of Application: Oral Exposure Time: (1-39W PREG) Result: Specific Developmental Abnormalities: Skin and skin appendages. Specific Developmental Abnormalities: Other developmental abnormalities. Specific Developmental Abnormalities: Musculoskeletal system. Species: Woman Dose: 3675 MG/KG FLUKA - 43070 www.sigma-aldrich.com Page 7

Route of Application: Unreported Exposure Time: (1-35W PREG) Result: Specific Developmental Abnormalities: Skin and skin appendages. Effects on Newborn: Physical. Effects on Newborn: Delayed effects. Species: Woman Dose: 1620 MG/KG Route of Application: Unreported Exposure Time: (1-39W PREG) Result: Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Effects on Newborn: Other postnatal measures or effects. Species: Rat Dose: 800 MG/KG Route of Application: Oral Exposure Time: (11-14D PREG) Result: Specific Developmental Abnormalities: Eye, ear. Species: Rat Dose: 1300 MG/KG Route of Application: Oral Exposure Time: (7-19D PREG) Result: Effects on Newborn: Behavioral. Effects on Newborn: Growth statistics (e.g., reduced weight gain). Specific Developmental Abnormalities: Musculoskeletal system. Species: Rat Dose: 2400 MG/KG Route of Application: Oral Exposure Time: (7-18D PREG) Result: Effects on Newborn: Growth statistics (e.g., reduced weight gain). Specific Developmental Abnormalities: Central nervous system. Species: Rat Dose: 338 MG/KG Route of Application: Intraperitoneal Exposure Time: (12-14D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Specific Developmental Abnormalities: Body wall. Species: Rat Dose: 150 MG/KG Route of Application: Intraperitoneal Exposure Time: (11D PREG) Result: Specific Developmental Abnormalities: Central nervous system. Specific Developmental Abnormalities: Urogenital system. Species: Rat Dose: 100 MG/KG Route of Application: Intraperitoneal Exposure Time: (11D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Embryo or Fetus: Fetal death. Species: Rat Dose: 150 MG/KG Route of Application: Intraperitoneal Exposure Time: (14D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal FLUKA - 43070 www.sigma-aldrich.com Page 8

system. Species: Rat Dose: 900 MG/KG Route of Application: Subcutaneous Exposure Time: (10-15D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Species: Rat Dose: 600 MG/KG Route of Application: Subcutaneous Exposure Time: (13-15D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Mouse Dose: 640 MG/KG Route of Application: Oral Exposure Time: (14D PRE/1-18D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Species: Mouse Dose: 150 MG/KG Route of Application: Oral Exposure Time: (6-15D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Species: Mouse Dose: 400 MG/KG Route of Application: Oral Exposure Time: (9-18D PREG) Result: Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Immune and reticuloendothelial system. Species: Mouse Dose: 45 MG/KG Route of Application: Oral Exposure Time: (12D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Mouse Dose: 58 MG/KG Route of Application: Intraperitoneal Exposure Time: (13D PREG) Result: Effects on Embryo or Fetus: Cytological changes (including somatic cell genetic material). Species: Mouse Dose: 75 MG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Effects on Embryo or Fetus: Other effects to embryo. Species: Mouse Dose: 50 MG/KG Route of Application: Intraperitoneal FLUKA - 43070 www.sigma-aldrich.com Page 9

Exposure Time: (13D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Species: Mouse Dose: 100 MG/KG Route of Application: Intramuscular Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Mouse Dose: 88 MG/KG Route of Application: Parenteral Exposure Time: (9D PREG) Result: Effects on Embryo or Fetus: Other effects to embryo. Species: Mouse Dose: 263 MG/KG Route of Application: Parenteral Exposure Time: (11-13D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Mouse Dose: 75 MG/KG Route of Application: Unreported Exposure Time: (9D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Species: Mouse Dose: 106 MG/KG Route of Application: Unreported Exposure Time: (8-10D PREG) Result: Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Specific Developmental Abnormalities: Musculoskeletal system. Species: Monkey Dose: 210 MG/KG Route of Application: Unreported Exposure Time: (25-45D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Species: Rabbit Dose: 300 MG/KG Route of Application: Oral Exposure Time: (16D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Species: Rabbit Dose: 450 MG/KG Route of Application: Oral Exposure Time: (14-16D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Rabbit Dose: 450 MG/KG FLUKA - 43070 www.sigma-aldrich.com Page 10

Route of Application: Unreported Exposure Time: (6-8D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). CHRONIC EXPOSURE - MUTAGEN Result: Laboratory experiments have shown mutagenic effects. Species: Human Dose: 360 UMOL/L Cell Type: lymphocyte Mutation test: DNA inhibition Species: Human Dose: 40 MG/L Cell Type: lymphocyte Mutation test: Cytogenetic analysis Species: Human Dose: 100 UG/L Cell Type: leukocyte Mutation test: Cytogenetic analysis Species: Rat Route: Oral Dose: 1260 MG/KG Exposure Time: 6W Mutation test: Morphological transformation. Species: Mouse Route: Intraperitoneal Dose: 10 MG/KG Mutation test: Sister chromatid exchange Species: Hamster Dose: 100 MG/L Cell Type: Embryo Mutation test: Morphological transformation. Species: Hamster Dose: 1600 MG/L Cell Type: ovary Mutation test: Sister chromatid exchange CHRONIC EXPOSURE - REPRODUCTIVE HAZARD Species: Woman Dose: 3240 MG/KG Route of Application: Oral Exposure Time: (1-39W PREG) Result: Effects on Newborn: Physical. Effects on Newborn: Behavioral. Effects on Newborn: Growth statistics (e.g., reduced weight gain). Species: Woman Dose: 540 MG/KG Route of Application: Unreported Exposure Time: (1-39W PREG) Result: Effects on Newborn: Growth statistics (e.g., reduced weight gain). Species: Rat FLUKA - 43070 www.sigma-aldrich.com Page 11

Dose: 50 MG/KG Route of Application: Oral Exposure Time: (7-16D PREG) Result: Effects on Newborn: Biochemical and metabolic. Species: Rat Dose: 2400 MG/KG Route of Application: Oral Exposure Time: (7-18D PREG) Result: Effects on Newborn: Behavioral. Effects on Newborn: Growth statistics (e.g., reduced weight gain). Effects on Newborn: Viability index (e.g., # alive at day 4 per # born alive). Species: Rat Dose: 540 MG/KG Route of Application: Oral Exposure Time: (9-17D PREG) Result: Effects on Fertility: Litter size (e.g.; # fetuses per litter; measured before birth). Effects on Embryo or Fetus: Fetal death. Species: Rat Dose: 600 MG/KG Route of Application: Oral Exposure Time: (7-18D PREG) Result: Effects on Newborn: Behavioral. Species: Rat Dose: 2400 MG/KG Route of Application: Oral Exposure Time: (7-18D PREG) Result: Effects on Newborn: Behavioral. Effects on Newborn: Live birth index (# fetuses per litter; measured after birth). Maternal Effects: Other effects. Species: Rat Dose: 50 MG/KG Route of Application: Intraperitoneal Exposure Time: (1D PRE) Result: Maternal Effects: Menstrual cycle changes or disorders. Effects on Fertility: Other measures of fertility Species: Rat Dose: 900 MG/KG Route of Application: Subcutaneous Exposure Time: (10-15D PREG) Result: Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Species: Rat Dose: 120 MG/KG Route of Application: Subcutaneous Exposure Time: (15-22D PREG) Result: Effects on Newborn: Behavioral. Species: Rat Dose: 1050 MG/KG Route of Application: Subcutaneous FLUKA - 43070 www.sigma-aldrich.com Page 12

Exposure Time: (1-21D PREG) Result: Effects on Newborn: Other postnatal measures or effects. Species: Rat Dose: 4800 MG/KG Route of Application: Subcutaneous Exposure Time: (60D MALE) Result: Effects on Fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females). Species: Rat Dose: 4800 MG/KG Route of Application: Parenteral Exposure Time: (60D MALE) Result: Effects on Fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females). Species: Mouse Dose: 85 MG/KG Route of Application: Oral Exposure Time: (10D PREG) Result: Effects on Fertility: Abortion. Species: Mouse Dose: 630 MG/KG Route of Application: Oral Exposure Time: (8-12D PREG) Result: Effects on Newborn: Growth statistics (e.g., reduced weight gain). Effects on Newborn: Viability index (e.g., # alive at day 4 per # born alive). Effects on Newborn: Live birth index (# fetuses per litter; measured after birth). Species: Mouse Dose: 88 MG/KG Route of Application: Intraperitoneal Exposure Time: (9D PREG) Result: Effects on Newborn: Biochemical and metabolic. Species: Mouse Dose: 150 MG/KG Route of Application: Intraperitoneal Exposure Time: (11-13D PREG) Result: Effects on Fertility: Pre-implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Mouse Dose: 88 MG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Specific Developmental Abnormalities: Central nervous system. Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Species: Mouse Dose: 100 MG/KG FLUKA - 43070 www.sigma-aldrich.com Page 13

Route of Application: Subcutaneous Exposure Time: (11D PREG) Result: Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Species: Mammal Dose: 330 MG/KG Route of Application: Oral Exposure Time: (8-18D PREG) Result: Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Effects on Embryo or Fetus: Fetal death. Section 12 - Ecological Information No data available. Section 13 - Disposal Considerations APPROPRIATE METHOD OF DISPOSAL OF SUBSTANCE OR PREPARATION Contact a licensed professional waste disposal service to dispose of this material. Observe all federal, state, and local environmental regulations. (DN)Requires special label: "Contains a substance which is regulated by Dannish work environmental law due to the risk of carcinogenic properties." Section 14 - Transport Information DOT Proper Shipping Name: None Non-Hazardous for Transport: This substance is considered to be non-hazardous for transport. IATA Non-Hazardous for Air Transport: Non-hazardous for air transport. Section 15 - Regulatory Information EU ADDITIONAL CLASSIFICATION Symbol of Danger: T Indication of Danger: Toxic. R: 45-61-22 Risk Statements: May cause cancer. May cause harm to the unborn child. Harmful if swallowed. S: 53-45 Safety Statements: Avoid exposure - obtain special instructions before use. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). US CLASSIFICATION AND LABEL TEXT Indication of Danger: Toxic. Risk Statements: May cause cancer. May cause harm to the unborn child. Harmful if swallowed. Safety Statements: Avoid exposure - obtain special instructions before use. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). US Statements: Target organ(s): Central nervous system. Blood. Calif. Prop. 65 carcinogen & developmental hazard. UNITED STATES REGULATORY INFORMATION SARA LISTED: Yes FLUKA - 43070 www.sigma-aldrich.com Page 14

DEMINIMIS: 0.1 % NOTES: This product is subject to SARA section 313 reporting requirements. UNITED STATES - STATE REGULATORY INFORMATION CALIFORNIA PROP - 65 California Prop - 65: This product is or contains chemical(s) known to the state of California to cause developmental toxicity. This product is or contains chemical(s) known to the state of California to cause cancer. This product is or contains chemical(s) known to the state of California to cause cancer. This product is or contains chemical(s) known to the state of California to cause developmental toxicity. CANADA REGULATORY INFORMATION WHMIS Classification: This product has been classified in accordance with the hazard criteria of the CPR, and the MSDS contains all the information required by the CPR. DSL: No NDSL: No Section 16 - Other Information DISCLAIMER For R&D use only. Not for drug, household or other uses. WARRANTY The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale. Copyright 2010 Sigma-Aldrich Co. License granted to make unlimitedpaper copies for internal use only.

FLUKA - 43070

www.sigma-aldrich.com

Page

15